Drug pricing group launches six-figure ad buy pressuring Congress to act

Drug pricing group launches six-figure ad buy pressuring Congress to act
© Getty Images

A leading advocacy group is launching a six-figure ad campaign pressuring Congress to act to lower drug prices.

The TV and digital ads from the Campaign for Sustainable Rx Pricing, a coalition of insurers, hospitals and other groups, come at a time when hopes are high for action on drug prices.

Democrats have vowed to take steps to reduce drug prices, and they will control the House next year. In addition, President TrumpDonald John TrumpImpeachment? Not so fast without missing element of criminal intent Feds say marijuana ties could prevent immigrants from getting US citizenship Trump approval drops to 2019 low after Mueller report's release: poll MORE has repeatedly talked of efforts to reduce drug prices.

The ad shows a man writing a letter to Congress, saying, “Drug prices are going up, every single day. It's price gouging. When will you take action?”

“Congress: You promised lower drug prices. Keep your commitment,” the ad ends.

Advocates are hoping that the combination of the Democratic House and Trump will lead to action. But any drug pricing measures face an uphill climb, given that drug companies are still a powerful force in Washington and Republicans control the Senate.

Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellFormer Bush assistant: Mueller report makes Obama look 'just plain bad' 20 years after Columbine, Dems bullish on gun reform Dem says marijuana banking bill will get House vote this spring MORE (R-Ky.) did say last week that he thinks drug pricing will be on the agenda, though he did not provide details.

“I can’t imagine that that won’t be on the agenda,” he said.

The Campaign for Sustainable Rx Pricing is pushing for ideas like easing approvals of cheaper generic drugs to increase competition, and increasing transparency around drug costs.

Democrats are pushing to go further and enact ideas like allowing Medicare to negotiate drug prices.